The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...

The complaint argues Kennedy’s actions to remove the COVID vaccine from the CDC's immunization schedule for pregnant people ...

Milestone Pharmaceuticals Inc. is a strong buy under $2 with FDA approval for Cardamyst expected in 2026, offering unique ...